| 000 | 01694 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517202845.0 | ||
| 264 | 0 | _c20180830 | |
| 008 | 201808s 0 0 eng d | ||
| 022 | _a2476-762X | ||
| 024 | 7 |
_a10.22034/APJCP.2018.19.2.331 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRasheed, Afshan Asghar | |
| 245 | 0 | 0 |
_aCd20 Expression and Effects on Outcome of Relapsed/
Refractory Diffuse Large B Cell Lymphoma after Treatment
with Rituximab _h[electronic resource] |
| 260 |
_bAsian Pacific journal of cancer prevention : APJCP _cFeb 2018 |
||
| 300 |
_a331-335 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntigens, CD20 _xmetabolism |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xmetabolism |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, Large B-Cell, Diffuse _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasm Recurrence, Local _xdiagnosis |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aRituximab _xtherapeutic use |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aSamad, Adeel | |
| 700 | 1 | _aRaheem, Ahmed | |
| 700 | 1 | _aHirani, Samina Ismail | |
| 700 | 1 | _aShabbir- Moosajee, Munira | |
| 773 | 0 |
_tAsian Pacific journal of cancer prevention : APJCP _gvol. 19 _gno. 2 _gp. 331-335 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.22034/APJCP.2018.19.2.331 _zAvailable from publisher's website |
| 999 |
_c28121661 _d28121661 |
||